China Transcenta’s Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019. I did not want to work on an antibody similar to the dozens already in clinical trials, I wanted to…
See our Cookie Privacy Policy Here